| | | | | | Präparat | Packungsgrösse | EFP | PP | SB | TK | Zusammensetzung | Zulassungsinhaber | Kat. | | |
|---|
| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | R | S | T | U | V | X | Z |
| | | FI | PI | BM | Seresta | 20 Comprimé(s) | 1.96 | 11.35 | 10% | | Comprimés: Oxazepamum 15 mg | Viatris Pharma GmbH | B / SL / SO | FB | G |
| | | FI | PI | BM | Seresta | 50 Comprimé(s) | 4.26 | 13.85 | 10% | | Comprimés: Oxazepamum 15 mg | Viatris Pharma GmbH | B / SL / SO | FB | G |
| | | FI | PI | BM | Sevre-Long 30 mg | 30 Gélule(s) | 20.28 | 38.45 | 10% | | Capsules retard: Morphini Sulfas Pentahydricus 30 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | G |
| | | FI | PI | BM | Sevre-Long 60 mg | 30 Gélule(s) | 33.27 | 52.60 | 10% | | Capsules retard: Morphini Sulfas Pentahydricus 60 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | G |
| | | FI | PI | BM | Sevre-Long 120 mg | 30 Gélule(s) | 54.52 | 75.70 | 10% | | Capsules retard: Morphini Sulfas Pentahydricus 120 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | G |
| | | FI | PI | BM | Sevre-Long 200 mg - T | 30 Gélule(s) | 60.92 | 82.65 | 10% | | Capsules retard: Morphini Sulfas Pentahydricus 200 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | G |
| | | FI | PI | BM | Sevredol 10 mg | 20 Comprimé(s) | 6.99 | 16.85 | 10% | | Comprimés filmés: Morphini Sulfas Pentahydricus 10 mg | Mundipharma Medical
Company, Hamilton,
Bermuda, Basel Branch | A+ / SL | FB | G |
| | | FI | PI | BM | Seresta forte | 20 Comprimé(s) | 4.79 | 14.45 | 10% | | Comprimés: Oxazepamum 50 mg | Viatris Pharma GmbH | B / SL | FB | G |
| | | FI | PI | BM | Seresta forte | 100 Comprimé(s) | 18.58 | 36.60 | 10% | | Comprimés: Oxazepamum 50 mg | Viatris Pharma GmbH | B / SL | FB | G |
| | | FI | PI | BM | Stilnox CR 6.25 mg | 14 Comprimé(s) | 1.91 | 11.30 | 10% | | comprimés à libération contrôlée: Zolpidemi Tartras 6.25 mg | Sanofi-Aventis
(Suisse) SA | B / SL | FB | G |
| | | FI | PI | BM | Stilnox CR 12.5 mg | 14 Comprimé(s) | 3.23 | 12.75 | 10% | | comprimés à libération contrôlée: Zolpidemi Tartras 12.5 mg | Sanofi-Aventis
(Suisse) SA | B / SL | FB | G |
| | | FI | | BM | Sufenta | 5 1 ampoule(s) à 2 ml | | | k.A. | | Solution injectable: Sufentanilum 5 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | G |
| | | FI | | BM | Sufenta | 5 1 ampoule(s) à 10 ml | | | k.A. | | Solution injectable: Sufentanilum 5 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | G |
| | | FI | | BM | Sufenta forte | 5 1 ampoule(s) à 1 ml | | | k.A. | | Solution injectable: Sufentanilum 50 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | G |
| | | FI | | BM | Sufenta forte | 5 1 ampoule(s) à 5 ml | | | k.A. | | Solution injectable: Sufentanilum 50 µg/ml | Piramal Critical Care
Limited, London,
Zweigniederlassung
Rüschlikon | A+ | FB | G |
| | | FI | PI | BM | Stilnox ‐ F - T | 10 Comprimé(s) | 2.78 | 7.30 | k.A. | | Comprimés sécables: Zolpidemi Tartras 10 mg | Sanofi-Aventis
(Suisse) SA | B | FB | G |
| | | FI | PI | BM | Stilnox ‐ F - T | 30 Comprimé(s) | 7.20 | 16.45 | k.A. | | Comprimés sécables: Zolpidemi Tartras 10 mg | Sanofi-Aventis
(Suisse) SA | B | FB | G |
| | | FI | PI | BM | Stilnox CR 6.25 mg | 28 Comprimé(s) | 3.41 | 12.95 | k.A. | | comprimés à libération contrôlée: Zolpidemi Tartras 6.25 mg | Sanofi-Aventis
(Suisse) SA | B | FB | G |
| | | FI | PI | BM | Stilnox CR 12.5 mg | 28 Comprimé(s) | 5.77 | 15.50 | k.A. | | comprimés à libération contrôlée: Zolpidemi Tartras 12.5 mg | Sanofi-Aventis
(Suisse) SA | B | FB | G |
| | | FI | PI | BM | Stilnox CR 6.25 mg | 7 Comprimé(s) | | | 10% | | comprimés à libération contrôlée: Zolpidemi Tartras 6.25 mg | Sanofi-Aventis
(Suisse) SA | B | FB | G |
| | | FI | PI | BM | Stilnox CR 12.5 mg | 7 Comprimé(s) | | | 10% | | comprimés à libération contrôlée: Zolpidemi Tartras 12.5 mg | Sanofi-Aventis
(Suisse) SA | B | FB | G |
